DDInter336 DDInter870
Celecoxib, a selective cyclooxygenase-2 (COX-2) inhibitor, is a nonsteroidal anti-inflammatory drug (NSAID) which is known for its decreased risk of causing gastrointestinal bleeding compared to other NSAIDS. It is used to manage symptoms of various types of arthritis pain and in familial adenomatous polyposis (FAP) to reduce precancerous polyps in the colon. It is marketed by Pfizer under the brand name Celebrex, and was initially granted FDA approval in 1998. Interestingly, selective COX-2 inhibitors (especially celecoxib), have been evaluated as potential cancer chemopreventive and therapeutic drugs in clinical trials for a variety of malignancies.
Cytomegalovirus immunoglobulin is obtained from pooled adult human plasma selected for high titers of antibody for cytomegalovirus (CMV). It contains purified immunoglobulin G (IgG) antibodies targeting cytomegalovirus (CMV)[FDA label]. Cytomegalovirus, a member of the herpes virus family, is ubiquitous the human population, leading to infections which are followed by life-long dormancy in the host with occasional reactivations and recurrent infections. The seroprevalence of antibodies in adults ranges from 40-100 % with an inverse correlation to socioeconomic status. The transmission of cytomegalovirus infection requires intimate contact with infected excretions such as saliva, urine, cervical and vaginal excretions, semen, breast milk and blood . CMV infection can lead to a high fever and severe organ-specific damage with significant morbidity and mortality rates. Cytomegalovirus (CMV) may lead to a wide spectrum of infection in immunocompetent hosts. Sites most often involved include the lung (severe community-acquired viral pneumonia), liver (transaminitis), spleen (splenomegaly), GI tract (colitis), CNS (encephalitis), the hematologic system (cytopenias), and multisystem involvement . During the span of an individual's life, the virus may reactivate, resulting in repeated shedding and spread of the virus. Molecular mechanisms have been identified by which show that CMVs interfere with the host immune system. Finally, however, the infection is normally controlled by the host's immune response. As a consequence, CMV disease is restricted to the immunocompromised or immunologically immature host, in which it can lead the devastating result of transplant rejection , .
Celecoxib {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Diclofenac
Diclofenac {u} may lead to a major life threatening interaction when taken with {v} Human cytomegalovirus immune globulin
Celecoxib {u} (Compound) palliates {v} (Disease) systemic scleroderma
systemic scleroderma {u} (Disease) is palliated by {v} (Compound) Diclofenac
Diclofenac {u} may lead to a major life threatening interaction when taken with {v} Human cytomegalovirus immune globulin
Celecoxib {u} (Compound) palliates {v} (Disease) systemic scleroderma
systemic scleroderma {u} (Disease) is treated by {v} (Compound) Methotrexate
Methotrexate {u} may lead to a major life threatening interaction when taken with {v} Human cytomegalovirus immune globulin
Celecoxib {u} (Compound) binds {v} (Gene) PTGS2
PTGS2 {u} (Gene) is bound by {v} (Compound) and {u} (Gene) is upregulated by {v} (Compound) Sulfasalazine
Sulfasalazine {u} may lead to a major life threatening interaction when taken with {v} Human cytomegalovirus immune globulin
Celecoxib {u} (Compound) binds {v} (Gene) PTGS2
PTGS2 {u} (Gene) is upregulated by {v} (Compound) Bacitracin
Bacitracin {u} may lead to a major life threatening interaction when taken with {v} Human cytomegalovirus immune globulin
Celecoxib {u} (Compound) is included by {v} (Pharmacologic Class) Nonsteroidal Anti-inflammatory Compounds
Nonsteroidal Anti-inflammatory Compounds {u} (Pharmacologic Class) includes {v} (Compound) Diclofenac
Diclofenac {u} may lead to a major life threatening interaction when taken with {v} Human cytomegalovirus immune globulin
Celecoxib {u} (Compound) causes {v} (Side Effect) Cardiac disorder
Cardiac disorder {u} (Side Effect) is caused by {v} (Compound) Diclofenac
Diclofenac {u} may lead to a major life threatening interaction when taken with {v} Human cytomegalovirus immune globulin
Celecoxib {u} (Compound) upregulates {v} (Gene) ST3GAL5
ST3GAL5 {u} (Gene) is upregulated by {v} (Compound) Sirolimus
Sirolimus {u} may lead to a major life threatening interaction when taken with {v} Human cytomegalovirus immune globulin
Celecoxib {u} (Compound) upregulates {v} (Gene) RRS1
RRS1 {u} (Gene) is downregulated by {v} (Compound) Sirolimus
Sirolimus {u} may lead to a major life threatening interaction when taken with {v} Human cytomegalovirus immune globulin
Celecoxib {u} (Compound) resembles {v} (Compound) Sulfaphenazole
Sulfaphenazole {u} (Compound) resembles {v} (Compound) Sulfasalazine
Sulfasalazine {u} may lead to a major life threatening interaction when taken with {v} Human cytomegalovirus immune globulin
Celecoxib (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Diclofenac (Compound) and Diclofenac may lead to a major life threatening interaction when taken with Human cytomegalovirus immune globulin
Celecoxib (Compound) palliates systemic scleroderma (Disease) and systemic scleroderma (Disease) is palliated by Diclofenac (Compound) and Diclofenac may lead to a major life threatening interaction when taken with Human cytomegalovirus immune globulin
Celecoxib (Compound) palliates systemic scleroderma (Disease) and systemic scleroderma (Disease) is treated by Methotrexate (Compound) and Methotrexate may lead to a major life threatening interaction when taken with Human cytomegalovirus immune globulin
Celecoxib (Compound) binds PTGS2 (Gene) and PTGS2 (Gene) is bound by Sulfasalazine (Compound) and PTGS2 (Gene) is upregulated by Sulfasalazine (Compound) and Sulfasalazine may lead to a major life threatening interaction when taken with Human cytomegalovirus immune globulin
Celecoxib (Compound) binds PTGS2 (Gene) and PTGS2 (Gene) is upregulated by Bacitracin (Compound) and Bacitracin may lead to a major life threatening interaction when taken with Human cytomegalovirus immune globulin
Celecoxib (Compound) is included by Nonsteroidal Anti-inflammatory Compounds (Pharmacologic Class) and Nonsteroidal Anti-inflammatory Compounds (Pharmacologic Class) includes Diclofenac (Compound) and Diclofenac may lead to a major life threatening interaction when taken with Human cytomegalovirus immune globulin
Celecoxib (Compound) causes Cardiac disorder (Side Effect) and Cardiac disorder (Side Effect) is caused by Diclofenac (Compound) and Diclofenac may lead to a major life threatening interaction when taken with Human cytomegalovirus immune globulin
Celecoxib (Compound) upregulates ST3GAL5 (Gene) and ST3GAL5 (Gene) is upregulated by Sirolimus (Compound) and Sirolimus may lead to a major life threatening interaction when taken with Human cytomegalovirus immune globulin
Celecoxib (Compound) upregulates RRS1 (Gene) and RRS1 (Gene) is downregulated by Sirolimus (Compound) and Sirolimus may lead to a major life threatening interaction when taken with Human cytomegalovirus immune globulin
Celecoxib (Compound) resembles Sulfaphenazole (Compound) and Sulfaphenazole (Compound) resembles Sulfasalazine (Compound) and Sulfasalazine may lead to a major life threatening interaction when taken with Human cytomegalovirus immune globulin